January 15, 2020
Editor's note: The original version of this story claimed that STARS-ADHD Adjunctive enrolled 2016 subjects, instead of 206. We apologize for this error.
Digital therapeutic company Akili Interactive has announced the first results of an open-label, multisite pediatric ADHD trial providing some patients with the company’s video game-like treatment alongside a stimulant medication.
Called the ...
March 7, 2019
Boston-based Akili Interactive Labs, maker of video game-like treatments for children with ADHD and autism spectrum disorder, has found a partner to help promote its digital therapeutic products in eastern Asia.
Thanks to a new strategic partnership announced this morning, Osaka, Japan-based pharmaceutical company Shionogi will take over the commercialization, marketing, clinical development and...
Left to right: Dr. Daniel Kraft, Fitbit's Any McDonough, Verily's Dr. Jess Mega and Akili's Eddie Martucci chat on stage at CES 2019’s Digital Health Summit
January 9, 2019
Digital therapeutics are a nascent corner of the healthcare technology industry. With few precedents available outside of novel drugs or medical devices, it would make sense that Pear Therapeutics, Proteus and other digital therapeutics companies furthest along the regulatory pipeline align themselves with industry partners well versed in selling and supporting a medical product.
As such, it came...
January 3, 2019
A small feasibility study conducted by the Children’s Hospital of Philadelphia suggests that Project: Evo, the digital medicine developed by Akili Interactive Labs that is delivered via a video game, continually engaged children with autism spectrum disorder (ASD) and reduced their ADHD symptoms, although more objective measures of cognitive control were mixed.
Nineteen children aged...
August 9, 2018
Boston-based digital therapeutics company Akili Interactive Labs announced this morning that it has added an extra $13 million to its previously announced Series C financing. Together, this brings the company’s 2018 funding to $68 million, and its total backing to just over $140 million.
The additional investment from CLSA, Omidyar Technology Ventures, Digital Garage Group, and Fearless Ventures...
May 9, 2018
This morning, Boston-based Akili Interactive Labs announced the closure of a $55 million Series C funding round. The investment was led by Temasek, with participation from Baillie Gifford, Amgen Ventures, M Ventures, JAZZ Venture Partners, Canepa Advanced Healthcare Fund, and Brooklands Capital Strategies.
According to the company, this new funding will be used to support development, regulatory...
December 4, 2017
Boston-based Akili Interactive Labs has announced positive results from the largest clinical trial of its video game-based pediatric ADHD treatment yet. In light of these data, the company announced that it now plans to file AKL-T01, also known as Project: Evo ADHD Treatment, for FDA clearance as a novel treatment for children and adolescents with ADHD
“This is, any way you slice it, our largest...
November 1, 2016
In 2013, Nature told the world that NeuroRacer, the first health game from the research lab that would spin out to become Akili Labs, was a game changer. While Akili Labs cofounder and Chief Science Advisor Adam Gazzaley might quibble with the details, he definitely thinks mental healthcare is a game in need of a change.
“Every researcher wants the pun of ‘game change’ used as a headline in...
July 20, 2016
Digital medicine company Akili Interactive Labs announced an $11.9 million expansion of its recent Series B funding, adding new investors into the round and bringing the series total to $42.4 million.
The Dutch subsidiary of Merck Ventures, known as M Ventures in the US and Canada, and the venture arm of Amgen joined existing investors, which include Pfizer and Shire Pharmaceuticals. This means...
May 6, 2016
Akili Interactive Labs will soon launch a clinical trial, called STARS-ADHD, that will evaluate the efficacy of its video game intervention for children with ADHD. The company plans to enroll a minimum of 300 children aged 8 to 12 years for its double-blind, randomized, controlled trial.
“Project: EVO has shown early promise to help improve attention and neurocognition in cognitive disorders like...